InMed Pharmaceuticals Regains Nasdaq Compliance, Averting Delisting Threat
INM has more than doubled off its 52-week low of $0.575.
Summary
InMed Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price rule, removing the immediate threat of delisting.
Key Events · Corporate Governance and Compliance · INM
-
Regains Nasdaq Bid Price Compliance
The company received notice from Nasdaq on June 3, 2026, confirming its common shares traded above $1.00 for 10 consecutive business days (May 19 - June 2, 2026).
-
Delisting Threat Removed
This action resolves the previously disclosed non-compliance with Nasdaq Listing Rule 5550(a)(2), which had been issued on March 27, 2026.
-
Supports Pending Merger
Maintaining Nasdaq listing is crucial for the successful completion of the recently announced all-stock merger with Mentari Therapeutics.
Analysis · INM · Life Sciences
This filing reports that InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, removing an immediate delisting risk. This is a critical positive development, especially given the company's recent going concern warning and its pending all-stock merger with Mentari Therapeutics. Maintaining Nasdaq listing is essential for the merger's completion and for investor confidence.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.58 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.